Standard Approach to atMP tissue colLEction (SAMPLE)

“**先进治疗药物产品(ATMP)*是使用患者细胞作为‘药物’来治疗各种疾病的新一代疗法。**尽管已有令人鼓舞的结果，但这项技术复杂、昂贵，目前仅适用于少数患者。**2018*英国**在**细胞和基因治疗火箭**的支持下，形成了**三个先进治疗中心(ATTC)**的网络。ATTC网络的合作伙伴包括：ATMP开发商和制造商、国家血液服务、医院、大学、物流供应商、原材料供应商和技术供应商。该项目由**iMatch ATTC**(创新曼彻斯特高级治疗中心枢纽)领导，但涉及与其他两个ATTC米德兰和威尔士ATTC和北方联盟ATTC的合作，并引入一个新的合作伙伴(伦敦盖伊和圣托马斯医院)，以扩大ATTC以外的活动。这个**项目**“**样本**”将利用一群有着共同愿景的合作者，他们将更有效地合作，这样我们就可以开发一种标准化的方法来收集先进治疗药物产品制造所必需的基于组织和细胞的起始材料。这个项目联合了来自苏格兰、英格兰和威尔士的专家：NHS血液和移植公司、SNBTS、克里斯蒂NHS基金会信托基金、曼彻斯特大学NHS基金会信托基金、纽卡斯尔on Tyne医院NHS基金会信托基金和4家在提供先进疗法的不同方面具有特定专业知识的企业。这4个商业合作伙伴是；渐近、Autolus、细胞治疗和TrakCel以及来自全球制药制造商和技术提供商的3个非资助参与：诺华、吉利德和Terumo BCT。我们将专注于：协调患者细胞收集，处理和存储这些细胞，并使高效系统能够从患者或捐赠者那里收集**样本**，从而简化生产并使接受治疗的患者数量增加。英国在这些类型的治疗方面处于世界领先地位，Innovate UK的这项投资将建立在这些创新疗法和技术的基础上，从而改善英国人的生活，同时也使英国成为投资和其他非英国开发的疗法的目的地，无论是试验还是最终的标准疗法。“

"**Advance Therapy Medicinal Products (ATMPs)** **are a new generation of treatments which use patients' cells as 'drugs' to treat a variety of diseases.** Although encouraging results have been reported, this technology is complex, expensive and currently only available to small numbers of patients.In **2018** the **UK** have formed **a network of three Advanced Therapy Treatment Centres (ATTCs)** supported by the **Cell & Gene Therapy Catapult**. The ATTC network have partners made up of: ATMP developers & manufacturers, National Blood Services, Hospitals, Universities, logistics providers, raw materials suppliers & technology providers. This project is being led by the **iMATCH ATTC** (innovate Manchester Advanced Therapy Centre Hub) but involves collaboration with the other 2 ATTCs Midlands & Wales ATTC and Northern Alliance ATTC and introduces a new partner (Guy's & St Thomas's Hospital, London) to expand activities outside the ATTCs. This **Project** ""**SAMPLE**"" will harnesses a group of collaborators who share a vision of working more efficiently together so we can develop a standardised approach to the collection of tissue & cell based starting materials essential to the manufacture of Advanced Therapy Medicinal Products. Ultimately, making improvements enabling more life changing treatments to be provided to children and adults with cancer and non-cancer diseases.This project unites experts from Scotland, England & Wales: NHS Blood & Transplant, SNBTS, The Christie NHS Foundation Trust, Manchester University NHS Foundation Trust, The Newcastle upon Tyne Hospitals NHS Foundation Trust and 4 businesses with specific expertise in different aspects of delivering Advanced Therapies. The 4 commercial partners are; Asymptote, Autolus, Cellular Therapeutics & TrakCel as well as 3 non-funded participation from global medicine manufacturers and technology providers: Novartis, Gilead & Terumo BCT.We are going to focus on: coordinating patient cell collection, processing and storage of those cells and enabling efficient systems to collect **SAMPLES** from the patient or donor and so streamlining the manufacture and enabling an increase in the number of patients being treated.The UK is a world leader in these types of treatments and this investment by Innovate UK will build on these innovative therapies and technologies thereby improving the lives of the UK population but also making the UK a destination for both investment and also other non-UK developed therapies in both trials and ultimately standard therapies."